GATA2 and acute myeloid leukemia: Although the repositioning of the equivalent −77 kb GATA2 enhancer in humans has been shown to be important in t(3;3)(q21;q26) and inv(3)(q21;q26) in AML in activating MECOM (Bresnick & Johnson, 2019; Gröschel et al., 2014; Yamaoka et al., 2020), no germline variants have been reported in this enhancer to date, possibly a result of this region not being included in most screening protocols.